Truist Securities Reiterates Buy Rating on Rapport Therapeutics (RAPP): co 'well capitalized'
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $44.00 price target on Rapport Therapeutics (NASDAQ: RAPP)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
